Showing results (191-200 of 279) with videos related to
Sort By:
Pageof 28
Blood|June 24, 2005
Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutationJason Gotlib, Caroline Berubé, Joseph D Growney, et al.Leukemia|July 5, 2022
Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosisAndreas Reiter, Jason Gotlib, Iván Álvarez-Twose, et al.NEJM Evidence|August 26, 2025
Pemigatinib for Myeloid/Lymphoid Neoplasms with FGFR1 RearrangementSrdan Verstovsek, Jean-Jacques Kiladjian, Alessandro M Vannucchi, et al.Ebiomedicine|December 6, 2017
Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus ProposalPeter Valent, Cem Akin, Michel Arock, et al.The New England Journal of Medicine|May 10, 2013
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CMLJulia E Maxson, Jason Gotlib, Daniel A Pollyea, et al.American Journal of Hematology|March 31, 2012
Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH SymposiumOmar Abdel-Wahab, Animesh Pardanani, Olivier A Bernard, et al.Journal of Hematology & Oncology|February 24, 2017
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trialSrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.Allergy|October 7, 2022
Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromesPeter Valent, Amy D Klion, Florence Roufosse, et al.Journal of the National Comprehensive Cancer Network : JNCCN|November 15, 2013
Chronic Myelogenous Leukemia, Version 1.2014Susan O'Brien, Jerald P Radich, Camille N Abboud, et al.Ejhaem|August 21, 2023
Incidence of blast phase in myelofibrosis according to anemia severityBarbara Mora, Margherita Maffioli, Elisa Rumi, et al.Pageof 28